{
  "symbol": "OTLK",
  "company": "Outlook Therapeutics, Inc.",
  "generated_at": "2026-06-24T07:36:51.236Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-05-27T19:50:49.413Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) trigger an automatic skip. Furthermore, the stock has already surged 170% from its March low, and the balance sheet is critically distressed ($7.7M cash vs ~$27M near-term debt), making any structure highly speculative with poor risk/reward.",
      "trigger": "[insider_cluster_universe] 4 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-05-27T19:50:49.395Z",
      "skip": true,
      "reason": "Anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) trigger an automatic skip. Furthermore, the stock has already surged 170% from its March low, and the balance sheet is critically distressed ($7.7M cash vs ~$27M near-term debt), making any structure highly speculative with poor risk/reward.",
      "score": 9,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 0,
        "catalyst": 8,
        "mispricing": 0,
        "quality": 0,
        "technical": 1
      },
      "debug_path": "drafts/2026-05-27-OTLK.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-27T19:50:11.706Z",
      "summary": "OTLK has triggered on an insider cluster (4 directors buying open-market shares over May 26-27 at $0.40-$0.44, totaling ~$243K) coinciding with a major positive catalyst — the FDA granted its Formal Dispute Resolution appeal on May 26, concluding substantial evidence of effectiveness exists for LYTENAVA (bevacizumab-vikg) in neovascular AMD and directing staff to finalize labeling. The company plans a Class 1 BLA resubmission by June 2026 with an accelerated review timeline. However, the stock has already surged ~170% from its March low ($0.198) to $0.536 on this news, creating significant timing risk for new entry. Underlying fundamentals remain extremely distressed — pre-revenue, -$633M accumulated deficit, going-concern qualified financials, only $7.7M cash against near-term debt maturities of ~$27M, and massive ongoing dilution (shares outstanding doubled in 6 months to 105M). No 13F or politician trade data available. Options IV is extremely elevated (~160-215%), making premium collection strategies attractive for those who want exposure without directional risk at these levels.",
      "verdict": "range_bound_or_income",
      "confidence": 4,
      "tool_calls": 20,
      "walltime_min": 19,
      "debug_path": "dossiers/2026-05-27-OTLK.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "OTLK",
    "call": "HOLD",
    "confidence": 1,
    "score": 0,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_strong_down": "-2 (-81.2%)",
      "rsi_overbought": "-1 (77.3)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (23d ago)",
      "broken_below_high": "-2 (-42.8% from high)"
    },
    "summary": "HOLD (score +0) · 12-1 mom -81.2% · RSI 77.3 · above_both · -42.8% from high",
    "last_close": 1.7,
    "one_month_ago_close": 0.33,
    "twelve_month_ago_close": 1.77,
    "twelve_one_momentum_pct": -81.19,
    "rsi_14": 77.3,
    "ma_stack": "above_both",
    "from_period_high_pct": -42.76,
    "period_high": 2.97,
    "price_targets": {
      "bear": 0.5,
      "fair": 2.59,
      "bull": 10,
      "bear_return_pct": -70.6,
      "fair_return_pct": 52.4,
      "bull_return_pct": 488.2,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 0.5,
        "target_mean": 5.5,
        "target_high": 10,
        "analyst_count": 3
      }
    },
    "generated_at": "2026-06-24T07:36:51.233Z"
  }
}